The liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: A systematic review and meta-analysis - 11/10/20
, Fan Wang a, b , Qiu Zhao a, b, ⁎
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Highlights |
• | Our results also indicated that the prevalence of diarrhoea, nausea/vomiting, and abdominal pain in COVID-19 patients was 9.1%, 5.2%, and 3.5%, respectively. |
• | We found that 0.8-11% of COVID-19 patients had chronic liver comorbidities and 2.6-53% patients had abnormal levels of ALT, AST and TB, and 6-98% had abnormal levels of ALB during the COVID-19 progression. |
• | Meanwhile, diarrhea and nausea/vomiting were not associated with the COVID-19 progression and patient prognosis. |
Summary |
Backgrounds |
Since December 2019, novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19) occurred in Wuhan, and rapidly spread throughout China. Our study aimed to evaluate the association of liver injury and gastrointestinal symptoms (GIS) with the progression of COVID-19.
Methods |
A comprehensive search was performed on the PubMed to identify eligible studies that summarized the liver injury and GIS in COVID-19.
Results |
A total of 21 studies with 3024 patients were included. Up to 53% patients had liver dysfunctions and the degree of liver damage was associated the severity of the disease. The prevalence of diarrhoea, nausea/vomiting or abdominal pain in patients with COVID-19 were 9.1%, 5.2% and 3.5%, respectively. No significant was found in the prevalence of diarrhoea (OR, 1.24; 95%CI, 0.90 to 1.72; I2=0%, P=0.19) and nausea/vomiting (OR, 1.24; 95%CI, 0.57 to 2.69; I2=61%, P=0.58) between severe and non-severe patients. In addition, diarrhoea (OR, 1.22; 95%CI, 0.50 to 2.98; I2=0%, P=0.66) and nausea/vomiting (OR, 1.09; 95%CI, 0.46 to 2.62; I2=0%, P=0.84) were not associated with the prognosis of COVID-19 patients.
Conclusions |
The incidences of GIS in patients with COVID-19 is relatively low and are not associated with the COVID-19 progression. Gastroenterologists should pay more attention to the liver injury induced by SARS-CoV-2 during the course of infection.
El texto completo de este artículo está disponible en PDF.Keywords : COVID-19, SARS-CoV-2, Liver injury, Diarrhoea, Gastrointestinal symptoms
Esquema
Vol 44 - N° 5
P. 653-661 - octobre 2020 Regresar al número
Artículo precedente
- The MBOAT7 rs641738 variant is associated with an improved outcome in primary sclerosing cholangitis
- Cora Freund, Arne Wahlers, Nima Haji Begli, Yvonne Leopold, Petra Klöters-Plachky, Arianeb Mehrabi, Isabelle Mohr, Julia Sander, Christian Rupp, Daniel Nils Gotthardt, Karl Heinz Weiss
- Methylprednisolone-related liver injury: A descriptive study using the French pharmacovigilance database
- Judith Cottin, Sabrina Pierre, Véronique Pizzoglio, Corinne Simon, Geneviève Durrieu, Nathalie Bleyzac, Aurore Gouraud, Jérôme Dumortier
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.